UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped
UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped
Read moreThu, 24th Oct 2019 16:05
UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped
Read moreMotif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial
Read moreMotif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure
Read moreMotif Bio To Become Cash Shell If Restructuring Proposals Accepted
Read more(Alliance News) - Novel antibiotics-focused biopharmaceutical company Motif Bio PLC said Monday it has agreed with Hercules Capital Inc to postpone the next amortisation date for its loan and date
Read more(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J up 3.8%. The is
Read more(Alliance News) - Biopharmaceutical firm Motif Bio PLC said Monday that the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes.Shares a
Read more(Alliance News) - Biopharmaceutical firm Motif Bio PLC said on Thursday has amended its loan agreement with Hercules Capital Inc, delaying the next amortisation date by one month to September a to
Read more(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the terms of an agreed facility between the in at
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up
Read moreLONDON (Alliance News) - Motif Bio PLC on Friday said that shareholders voted against approval of the company's remuneration report.At the clinical-stage biopharmaceutical firm's on
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.
Read moreLONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's in the at
Read moreLONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive has as
Read moreLONDON (Alliance News) - Motif Bio PLC said Monday its 2018 loss narrowed significantly as research costs fell, despite an unexpected delay in its new drug application in the US.In 2018, to
Read more